Your browser doesn't support javascript.
loading
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.
Friedlander, Michael; Gebski, Val; Gibbs, Emma; Davies, Lucy; Bloomfield, Ralph; Hilpert, Felix; Wenzel, Lari B; Eek, Daniel; Rodrigues, Manuel; Clamp, Andrew; Penson, Richard T; Provencher, Diane; Korach, Jacob; Huzarski, Tomasz; Vidal, Laura; Salutari, Vanda; Scott, Clare; Nicoletto, Maria Ornella; Tamura, Kenji; Espinoza, David; Joly, Florence; Pujade-Lauraine, Eric.
Afiliación
  • Friedlander M; University of New South Wales Clinical School, Prince of Wales Hospital, Randwick, NSW, Australia. Electronic address: m.friedlander@unsw.edu.au.
  • Gebski V; NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia.
  • Gibbs E; NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia.
  • Davies L; NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia; Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Bloomfield R; AstraZeneca, Cambridge, UK.
  • Hilpert F; Jerusalem Hospital, Hamburg, Germany.
  • Wenzel LB; University of California, Irvine, CA, USA.
  • Eek D; AstraZeneca, Gothenburg, Sweden.
  • Rodrigues M; Institut Curie, Paris, France.
  • Clamp A; The Christie and University of Manchester, Manchester, UK.
  • Penson RT; Harvard Medical School, Boston, MA, USA.
  • Provencher D; University of Montreal, Montreal, QC, Canada.
  • Korach J; Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel.
  • Huzarski T; Pomeranian Medical University, Szczecin, Poland.
  • Vidal L; Hospital Clinic, Barcelona, Spain.
  • Salutari V; Policlinico Universitario Agostino Gemelli, Rome, Italy.
  • Scott C; The Walter and Eliza Hall Institute of Medical Research, Parkville, VA, Australia.
  • Nicoletto MO; Istituto Oncologico Veneto, Padova, Italy.
  • Tamura K; National Cancer Center Hospital, Tokyo, Japan.
  • Espinoza D; NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia.
  • Joly F; Centre François Baclesse, Caen, France.
  • Pujade-Lauraine E; Université Paris Descartes, AP-HP, Paris, France.
Lancet Oncol ; 19(8): 1126-1134, 2018 08.
Article en En | MEDLINE | ID: mdl-30026002
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ftalazinas / Piperazinas / Calidad de Vida / Carcinoma Epitelial de Ovario / Recurrencia Local de Neoplasia / Antineoplásicos Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ftalazinas / Piperazinas / Calidad de Vida / Carcinoma Epitelial de Ovario / Recurrencia Local de Neoplasia / Antineoplásicos Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article